The vast majority of people -- more than 90% -- with pain from cervical disc disease will get better on their own over time with simple, conservative treatments. Surgery, however, may help if ...
Genmab has received approval from the Japan's Ministry of Health, Labour and Welfare for Tivdak (tisotumab vedotin) to treat advanced or recurrent cervical cancer that progressed on or following ...
The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ (NASDAQ:GMAB) Tivdak (tisotumab vedotin) for advanced or recurrent cervical cancer that has progressed on or ...
The addition of AK104 to concurrent chemoradiotherapy improved survival outcomes for patients with locally advanced cervical ...
Cervical cancer incidence is rising, with rural and minoritized populations experiencing worse outcomes due to suboptimal care and screening disparities. Data from 2001-2019 reveal a widening gap ...
Japan approves Tivdak, the first ADC for cervical cancer, after Phase 3 trial shows a 30% reduction in death risk vs. chemotherapy. The trial of 502 patients showed Tivdak improved median overall ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback